NVAX PE Ratio & Valuation,Is NVAX Overvalued

NVAX Relative Valuation

NVAX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, NVAX is overvalued; if below, it's undervalued.

Historical Valuation

Novavax Inc (NVAX) is now in the Undervalued zone, suggesting that its current forward PS ratio of 2.09 is considered Undervalued compared with the five-year average of -0.52. The fair price of Novavax Inc (NVAX) is between 7770.97 to 7783.36 according to relative valuation methord. Compared to the current price of 7.62 USD , Novavax Inc is Undervalued By 99.9%.

Relative Value

Fair Zone

7770.97-7783.36

Current Price：7.62

99.9%

Undervalued

-9.03

11.53

EV/EBITDA

Novavax Inc. (NVAX) has a current EV/EBITDA of 11.53. The 5-year average EV/EBITDA is -12.37. The thresholds are as follows: Strongly Undervalued below -137.36, Undervalued between -137.36 and -74.87, Fairly Valued between 50.12 and -74.87, Overvalued between 50.12 and 112.61, and Strongly Overvalued above 112.61. The current Forward EV/EBITDA of 11.53 falls within the Historic Trend Line -Fairly Valued range.

8.72

EV/EBIT

Novavax Inc. (NVAX) has a current EV/EBIT of 8.72. The 5-year average EV/EBIT is 1.47. The thresholds are as follows: Strongly Undervalued below -30.12, Undervalued between -30.12 and -14.32, Fairly Valued between 17.27 and -14.32, Overvalued between 17.27 and 33.07, and Strongly Overvalued above 33.07. The current Forward EV/EBIT of 8.72 falls within the Historic Trend Line -Fairly Valued range.

2.09

Novavax Inc. (NVAX) has a current PS of 2.09. The 5-year average PS is 2.62. The thresholds are as follows: Strongly Undervalued below -1.63, Undervalued between -1.63 and 0.49, Fairly Valued between 4.74 and 0.49, Overvalued between 4.74 and 6.87, and Strongly Overvalued above 6.87. The current Forward PS of 2.09 falls within the Historic Trend Line -Fairly Valued range.

-1.18

P/OCF

Novavax Inc. (NVAX) has a current P/OCF of -1.18. The 5-year average P/OCF is -15.82. The thresholds are as follows: Strongly Undervalued below -139.99, Undervalued between -139.99 and -77.91, Fairly Valued between 46.26 and -77.91, Overvalued between 46.26 and 108.35, and Strongly Overvalued above 108.35. The current Forward P/OCF of -1.18 falls within the Historic Trend Line -Fairly Valued range.

6.85

P/FCF

Novavax Inc. (NVAX) has a current P/FCF of 6.85. The 5-year average P/FCF is 24.41. The thresholds are as follows: Strongly Undervalued below -206.04, Undervalued between -206.04 and -90.81, Fairly Valued between 139.64 and -90.81, Overvalued between 139.64 and 254.87, and Strongly Overvalued above 254.87. The current Forward P/FCF of 6.85 falls within the Historic Trend Line -Fairly Valued range.

Novavax Inc (NVAX) has a current Price-to-Book (P/B) ratio of -7.39. Compared to its 3-year average P/B ratio of -0.46 , the current P/B ratio is approximately 1511.24% higher. Relative to its 5-year average P/B ratio of 5.47, the current P/B ratio is about -235.16% higher. Novavax Inc (NVAX) has a Forward Free Cash Flow (FCF) yield of approximately -33.12%. Compared to its 3-year average FCF yield of -57.38%, the current FCF yield is approximately -42.28% lower. Relative to its 5-year average FCF yield of -38.45% , the current FCF yield is about -13.87% lower.

-7.39

P/B

Median3y

-0.46

Median5y

5.47

-33.12

FCF Yield

Median3y

-57.38

Median5y

-38.45

Competitors Valuation Multiple

The average P/S ratio for NVAX's competitors is 9272.56, providing a benchmark for relative valuation. Novavax Inc Corp (NVAX) exhibits a P/S ratio of 2.09, which is -99.98% above the industry average. Given its robust revenue growth of -16.64%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of NVAX decreased by 12.31% over the past 1 year. The primary factor behind the change was an decrease in Margin Expansion from -143.53 to -287.29.

The secondary factor is the Revenue Growth, contributed -16.64%to the performance.

Overall, the performance of NVAX in the past 1 year is driven by Margin Expansion. Which is more sustainable.

-16.64%

84.51M → 70.45M

Revenue Growth

100.16%

-143.53 → -287.29

Margin Expansion

-95.83%

82.58 → 3.44

P/E Change

-12.31%

8.69 → 7.62

Mkt Cap Growth

People Also Watch

Frequently Asked Questions

Is Novavax Inc (NVAX) currently overvalued or undervalued?

What is Novavax Inc (NVAX) fair value?

NVAX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Novavax Inc (NVAX) is between 7770.97 to 7783.36 according to relative valuation methord.

How does NVAX's valuation metrics compare to the industry average?

What is the current P/B ratio for Novavax Inc (NVAX) as of Jan 08 2026?

As of Jan 08 2026, Novavax Inc (NVAX) has a P/B ratio of -7.39. This indicates that the market values NVAX at -7.39 times its book value.

What is the current FCF Yield for Novavax Inc (NVAX) as of Jan 08 2026?

As of Jan 08 2026, Novavax Inc (NVAX) has a FCF Yield of -33.12%. This means that for every dollar of Novavax Inc’s market capitalization, the company generates -33.12 cents in free cash flow.

What is the current Forward P/E ratio for Novavax Inc (NVAX) as of Jan 08 2026?

As of Jan 08 2026, Novavax Inc (NVAX) has a Forward P/E ratio of -9.03. This means the market is willing to pay $-9.03 for every dollar of Novavax Inc’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for Novavax Inc (NVAX) as of Jan 08 2026?

As of Jan 08 2026, Novavax Inc (NVAX) has a Forward P/S ratio of 2.09. This means the market is valuing NVAX at $2.09 for every dollar of expected revenue over the next 12 months.

NVAX Valuation